Hot Sale for 6-Chloro-3-methyluracil - Indacaterol Maleate Intermediate CAS 312753-53-0 5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride High Purity – Ruifu

Manufacturer Supply; High Purity and Competitive Price
Commercial Supply Indacaterol Maleate (CAS: 753498-25-8) Related Intermediates:
5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride CAS: 312753-53-0
8-Benzyloxy-5-(2-Bromoacetyl)-2-Hydroxyquinoline CAS: 100331-89-3
5-(2R)-2-Oxiranyl-8-benzyloxy-2(1H)-quinolinone CAS: 173140-90-4
Indacaterol CAS: 312753-06-3

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Indacaterol Maleate (CAS: 753498-25-8) is a new, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist and bronchodilator,  is currently approved in Europe as Onbrez, and is marketed by Novartis. It needs to be taken only once a day, unlike competitors formoterol and salmeterol. Indacaterol Maleate (CAS: 753498-25-8) is used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Onbrez is administered via an aerosol formulation through a dry powder inhaler. A Phase III trial published in July 2010 suggested that indacaterol is significantly more effective than twice-daily formoterol in improving FEV1 and reduces the need for rescue medication.

The European Medicines Agency (EMA) approved indacaterol as a drug in 2009 under the Onbrez trade name while in the United States the Food and Drug Administration approved it under the trade name Arcapta in 2011. The drug is manufactured as its maleate salt form. Also, indacaterol is a chiral molecule; however, only the pure R-enantiomer is distributed. 

The chemical synthesis of Indacaterol Maleate (CAS: 753498-25-8) begins with a-chlorination of 5-acetyl-8-benzyloxy-2-quinolone with benzyltrimethylammonium dichloro-iodate. The resultant chloroketone is reduced with borane in tetrahydrofuran in the presence of the chiral boron catalyst R-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2c][ 1,3,2]oxazaborole to produce the corresponding chlorohydrin intermediate in high enantiomeric excess. The chlorohydrin intermediate is cyclized to the corresponding epoxide by treatment with potassium carbonate, the epoxide is condensed with 5,6-diethylindan-2-amine, and the benzyl protecting group is removed by hydrogenolysis to produce indacaterol. The 5,6-diethylindan-2-amine intermediate is derived from 1,2-diethylbenzene via Friedel-Crafts acylation with 3-chloropropionyl chloride, cyclization of the resultant 3-chloro- 1-(3,4-diethylphenyl)-1-propanone by means of concentrated sulfuric acid to 5,6-diethylindan-1-one, oximation with butyl nitrite, and reduction of the oxime to an amine via treatment with hydrogen over palladium- carbon.